EZRA · Reliance Global Group, Inc.

Reliance Global Group, Inc. (Nasdaq: EZRA) disclosed the formation of LifeSci Global Group LLC (LGG), a majority-owned subsidiary (51% owned by the Company), and a series of related transactions to invest in Innervate Radiopharmaceuticals LLC, an early-stage radiopharmaceutical company. The transactions were approved by independent directors due to related-party interests: CEO Ezra Beyman and director Scott Korman hold equity in LGG, and Korman serves as CEO of Innervate. The investment is structured through a $2,000,000 promissory note from EZRA International Group LLC (EIG), a wholly-owned subsidiary, to LGG, bearing 7% interest and maturing on April 29, 2031. LGG used the funds to subscribe for 421,053 Class A units of Innervate at $4.75 per unit, totaling $2,000,001.75, with $500,000 funded at closing and the remainder payable in monthly installments. LGG also received a priority distribution right of $4.75 per unit from a Priority Review Voucher sale or liquidity event, and warrants to purchase additional units. The press release highlights the strategic rationale: entry into late-stage radiopharmaceutical imaging for neuroblastoma, with potential expansion into cardiovascular and neurodegenerative markets. The investment is part of EZRA International Group's strategy to build exposure to high-growth healthcare platforms. The transactions resulted in changes to board committees: Scott Korman was removed from all committees, and independent directors were appointed.